Literature DB >> 14618355

[Analysis of risk factors and comparison of heparin and hemodilution therapies for retinal artery occlusion].

F Rüfer1, A Schröder, R Winter, C Erb.   

Abstract

No standards are available for the treatment of central retinal artery occlusion (CRAO). The aim of this study was to compare data about visual acuity development under heparin treatment with those from hemodilution. Data on 139 patients suffering from CRAO between 1991 and 2000 were examined retrospectively. Risk factors were listed. Therapies were compared in 38 of these patients, 23 of whom received full heparinization and 15 of whom received hemodilution. Many risk factors were shown. Neither therapy showed serious complications. Visual acuity improved significantly, by three or more lines, in five of 23 patients (21.7%) under full heparinization and six of 15 patients (40%) receiving hemodilution. Differences were not significant. For ethical reasons, the normal cause of disease in these patients cannot be studied and is still unknown. Because of many vascular risk factors, we recommend adapted therapies. Treatments should be examined in controlled studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14618355     DOI: 10.1007/s00347-002-0781-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  17 in total

1.  Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion.

Authors:  N H Atebara; G C Brown; J Cater
Journal:  Ophthalmology       Date:  1995-12       Impact factor: 12.079

2.  Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data.

Authors:  S Beatty; K G Au Eong
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

3.  [Erroneous vision determination and quantitative effects].

Authors:  J Petersen
Journal:  Ophthalmologe       Date:  1993-10       Impact factor: 1.059

4.  [Pathology of arterial and venous occlusive diseases of the retina (author's transl)].

Authors:  B Daicker
Journal:  Klin Monbl Augenheilkd       Date:  1977-02       Impact factor: 0.700

5.  Central retinal artery occlusion.

Authors:  H S Jenkins; D F Marcus
Journal:  JACEP       Date:  1979-09

6.  [Hyperbaric oxygen therapy in retinal artery occlusion].

Authors:  S Aisenbrey; R Krott; R Heller; D Krauss; G Rössler; K Heimann
Journal:  Ophthalmologe       Date:  2000-07       Impact factor: 1.059

7.  Report of general temporary anticoagulation in the treatment of acute cerebral and retinal ischaemia.

Authors:  E van den Berg; N Lohmann; D Friedburg; F Rabe
Journal:  Vasa       Date:  1997-08       Impact factor: 1.961

Review 8.  Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction.

Authors:  J H Chesebro; J J Badimon; A F Ortiz; B J Meyer; V Fuster
Journal:  Am J Cardiol       Date:  1993-12-16       Impact factor: 2.778

Review 9.  Oxygen radical mechanisms of brain injury following ischemia and reperfusion.

Authors:  R J Traystman; J R Kirsch; R C Koehler
Journal:  J Appl Physiol (1985)       Date:  1991-10

10.  Efficacy of high dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk.

Authors:  S C Heik; W Kupper; C Hamm; W Bleifeld; D H Koschyk; D Waters; C Chen
Journal:  J Am Coll Cardiol       Date:  1994-11-01       Impact factor: 24.094

View more
  3 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

2.  [Guidelines from the DOG, RG and BVA: retinal artery occlusion : November 2016 status].

Authors: 
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

3.  Surgical embolus removal in retinal artery occlusion.

Authors:  J García-Arumí; V Martinez-Castillo; A Boixadera; A Fonollosa; B Corcostegui
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.